{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:34:38Z","timestamp":1793406878744,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.xkme.2023.100783","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T20:16:55Z","timestamp":1702930615000},"page":"100783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial"],"prefix":"10.1016","volume":"6","author":[{"given":"Samy","family":"Hadjadj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Steubl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Mattheus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merlin C.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xkme.2023.100783_bib1","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.xkme.2023.100783_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1053\/j.ajkd.2017.04.025","article-title":"Risk of ESRD and mortality associated with change in filtration markers","volume":"70","author":"Rebholz","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.xkme.2023.100783_bib3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.xkme.2023.100783_bib4","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.xkme.2023.100783_bib5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.kint.2016.09.010","article-title":"Management of patients with diabetes and CKD: conclusions from a \u201cKidney Disease: improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"90","author":"Perkovic","year":"2016","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.xkme.2023.100783_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in Type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.xkme.2023.100783_bib7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in Type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.xkme.2023.100783_bib8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.xkme.2023.100783_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in Type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.xkme.2023.100783_bib10","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.xkme.2023.100783_bib11","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xkme.2023.100783_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101163","article-title":"Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials","volume":"41","author":"Staplin","year":"2021","journal-title":"Eclinicalmedicine"},{"issue":"3","key":"10.1016\/j.xkme.2023.100783_bib13","first-page":"391","article-title":"The effect of dapagliflozin on renal function in patients with type 2 diabetes","volume":"29","author":"Kohan","year":"2016","journal-title":"J\u00a0Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2023.100783_bib14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.xkme.2023.100783_bib15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1475-2840-13-102","article-title":"Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME)","volume":"13","author":"Zinman","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"10.1016\/j.xkme.2023.100783_bib16","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1681\/ASN.2018010103","article-title":"Empagliflozin and kidney function decline in patients with Type 2 diabetes: A slope analysis from the EMPA-REG OUTCOME trial","volume":"29","author":"Wanner","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"20","key":"10.1016\/j.xkme.2023.100783_bib17","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1001\/archinte.168.20.2212","article-title":"Rapid kidney function decline and mortality risk in older adults","volume":"168","author":"Rifkin","year":"2008","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.xkme.2023.100783_bib18","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1681\/ASN.2009050546","article-title":"Rapid decline of kidney function increases cardiovascular risk in the elderly","volume":"20","author":"Shlipak","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2023.100783_bib19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"22","key":"10.1016\/j.xkme.2023.100783_bib20","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.xkme.2023.100783_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.xkme.2023.100783_bib23","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.xkme.2023.100783_bib24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.xkme.2023.100783_bib25","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.xkme.2023.100783_bib26","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2337\/dc21-0076","article-title":"The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58","volume":"44","author":"Mosenzon","year":"2021","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.xkme.2023.100783_bib27","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.xkme.2023.100783_bib28","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the Dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.xkme.2023.100783_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A\u00a0pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.xkme.2023.100783_bib30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","article-title":"Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Heerspink","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.xkme.2023.100783_bib31","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.xkme.2023.100783_bib32","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/ndt\/gfac040","article-title":"Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial","volume":"37","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.xkme.2023.100783_bib33","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1016\/j.xkme.2023.100783_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.xkme.2023.100783_bib37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2337\/db20-303-OR","article-title":"303-OR: effect of dapagliflozin on risk for fast decline in EGFR: analyses from the DECLARE-TIMI 58 trial","volume":"69","author":"Raz","year":"2020","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.xkme.2023.100783_bib39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/2042018814544153","article-title":"Renal effects of dapagliflozin in patients with type 2 diabetes","volume":"5","author":"Thomas","year":"2014","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.xkme.2023.100783_bib40","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.xkme.2023.100783_bib41","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.xkme.2023.100783_bib42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in\u00a0vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.xkme.2023.100783_bib43","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","article-title":"Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration","volume":"57","author":"\u0160krti\u0107","year":"2014","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.xkme.2023.100783_bib44","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Ren Physiol"},{"issue":"suppl 1","key":"10.1016\/j.xkme.2023.100783_bib45","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2337\/db19-243-OR","article-title":"Dapagliflozin reduces measured GFR by reducing renal efferent arteriolar resistance in Type 2 diabetes","volume":"68","author":"Van Bommel","year":"2019","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.xkme.2023.100783_bib46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.xkme.2023.100783_bib48","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.kint.2019.12.021","article-title":"Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.xkme.2023.100783_bib49","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2023.100783_bib50","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059523002017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059523002017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:26:38Z","timestamp":1762910798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059523002017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2590059523002017"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2023.100783","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2023.100783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100783"}}